Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failure and relapse is known to be high for patients with isoniazid resistant TB treated with standard first line regimens. However, risk factors for unfavourable outcomes and the optimal treatment regimen for isoniazid resistant TB are unknown. This cohort study was conducted when Vietnam used the eight month first line treatment regimen and examined risk factors for failure/relapse among patients with isoniazid resistant TB. Methods Between December 2008 and June 2011 2090 consecutive HIV-negative adults (≥18 years of age) with new smear positive pulmonary TB presenting at participating district TB units in Ho Chi Minh City were recruited. Partici...
BACKGROUND: Studies have suggested that the Mycobacterium tuberculosis Beijing genotype causes more ...
BACKGROUND:Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis ...
Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the t...
Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failure...
BACKGROUND: Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failur...
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally in 2012. Among t...
(MTB) to anti-tuberculosis (TB) drugs presents a serious challenge to TB control worldwide. We inve...
AbstractIsoniazid mono-resistance is the most common first-line drug resistance in tuberculosis (TB)...
BACKGROUND There have been few studies on risk factors and treatment outcomes of isoniazid (H)-re...
Isoniazid resistance is highly prevalent in Vietnam.We investigated the molecular and epidemiologica...
Background: Patients completing treatment for tuberculosis (TB) in high-prevalence settings face a r...
Isoniazid resistance is highly prevalent in Vietnam. We investigated the molecular and epidemiologic...
<div><p>Background</p><p>Isoniazid and rifampicin are the two most efficacious first-line agents for...
; H-Isoniazid; R-Rifampicin; Z-Pyrazinamide; E-Ethambutol; S-Streptomycin) may be inadequate to trea...
The objective of the study: to identify risk factors for relapses in patients after the effective co...
BACKGROUND: Studies have suggested that the Mycobacterium tuberculosis Beijing genotype causes more ...
BACKGROUND:Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis ...
Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the t...
Background Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failure...
BACKGROUND: Drug resistant tuberculosis (TB) is increasing in prevalence worldwide. Treatment failur...
There were 8.6 million cases and 1.3 million deaths from tuberculosis (TB) globally in 2012. Among t...
(MTB) to anti-tuberculosis (TB) drugs presents a serious challenge to TB control worldwide. We inve...
AbstractIsoniazid mono-resistance is the most common first-line drug resistance in tuberculosis (TB)...
BACKGROUND There have been few studies on risk factors and treatment outcomes of isoniazid (H)-re...
Isoniazid resistance is highly prevalent in Vietnam.We investigated the molecular and epidemiologica...
Background: Patients completing treatment for tuberculosis (TB) in high-prevalence settings face a r...
Isoniazid resistance is highly prevalent in Vietnam. We investigated the molecular and epidemiologic...
<div><p>Background</p><p>Isoniazid and rifampicin are the two most efficacious first-line agents for...
; H-Isoniazid; R-Rifampicin; Z-Pyrazinamide; E-Ethambutol; S-Streptomycin) may be inadequate to trea...
The objective of the study: to identify risk factors for relapses in patients after the effective co...
BACKGROUND: Studies have suggested that the Mycobacterium tuberculosis Beijing genotype causes more ...
BACKGROUND:Isoniazid and rifampicin are the two most efficacious first-line agents for tuberculosis ...
Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the t...